ArticleCancer gene therapy2005
RNAi technology and lentiviral delivery as a powerful tool to suppress Tpr-Met-mediated tumorigenesis.
Article in Cancer gene therapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- Lack of Diaph3 relaxes the spindle checkpoint causing the loss of neural progenitors.Nature communications · 2016Article
- KLF4 is a key determinant in the development and progression of cerebral cavernous malformations.EMBO molecular medicine · 2016Article
- Article
- Inhibiting metastatic breast cancer cell migration via the synergy of targeted, pH-triggered siRNA delivery and chemokine axis blockade.Molecular pharmaceutics · 2014Article
- Targeting endothelial junctional adhesion molecule-A/ EPAC/ Rap-1 axis as a novel strategy to increase stem cell engraftment in dystrophic muscles.EMBO molecular medicine · 2014Article
- The diacylglycerol kinase α/atypical PKC/β1 integrin pathway in SDF-1α mammary carcinoma invasiveness.PloS one · 2014Article
- DNA triplex-mediated inhibition of MET leads to cell death and tumor regression in hepatoma.Cancer gene therapy · 2011Article
- Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth.The Journal of biological chemistry · 2010Article
- Curcuminoid-phospholipid complex induces apoptosis in mammary epithelial cells by STAT-3 signaling.Experimental & molecular medicine · 2008Article
- Triggered release of siRNA from poly(ethylene glycol)-protected, pH-dependent liposomes.Journal of controlled release : official journal of the Controlled Release Society · 2008Article
- Silencing the MET oncogene leads to regression of experimental tumors and metastases.Oncogene · 2008Article
- Biological role of the HGF/MET ligand/receptor couple in bovine mammary epithelial cells.Veterinary research communications · 2007Article
- Use of herpes simplex virus type 1-based amplicon vector for delivery of small interfering RNA.Gene therapy · 2007Article
- Development of a species-specific RNA polymerase I-based shRNA expression vector.Nucleic acids research · 2007Article
- Optimization of feline immunodeficiency virus vectors for RNA interference.Journal of virology · 2006Article
- Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas.Blood · 2006Article
- PRL-3 siRNA inhibits the metastasis of B16-BL6 mouse melanoma cells in vitro and in vivo.Molecular medicine (Cambridge, Mass.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
Abstract
Tpr-Met, the oncogenic counterpart of the Met receptor, has been detected in gastric cancers, as well as in precursor lesions and in the adjacent normal gastric mucosa. This has prompted the suggestion that Tpr-Met may predispose to the development of gastric tumors. Given the sequence specificity of RNA interference, oncogenes activated by point mutation or rearrangements can be targeted while spearing the product of the wild-type allele. In this work, we report specific suppression of Tpr-Met expression and inhibition of Tpr-Met-mediated transformation and tumorigenesis by means of a short interfering RNA (siRNA) directed toward the Tpr-Met junction (anti-TM2). When delivered by a lentiviral vector, anti-TM2 siRNA was effective also in mouse embryonal fibroblasts or epithelial cells expressing high levels of Tpr-Met. Our results suggest that lentiviral-mediated delivery of anti-TM2 siRNA may be developed into a powerful tool to treat Tpr-Met-positive cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.